SeaStar Medical Holding Corporation - Common Stock (ICU)
1.9000
+0.0900 (4.97%)
SeaStar Medical Holding Corporation is a biotechnology company focused on developing innovative therapies to enhance the treatment of life-threatening kidney conditions
The company is primarily engaged in researching and creating advanced medical devices and technologies designed to improve the care of patients with acute kidney injury and other renal-related disorders. By leveraging its proprietary approach, SeaStar Medical aims to provide solutions that reduce the need for dialysis and improve patient outcomes, ultimately transforming the standard of care in nephrology.
NEW YORK, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against SeaStar Medical Holding Corp (NASDAQICU) on behalf of long-term stockholders following a class action complaint that was filed against SeaStar on July 5, 2024 with a Class Period from October 31, 2022 to March 26, 2024. Our investigation concerns whether the board of directors of SeaStar have breached their fiduciary duties to the company.
SeaStar (NASDAQICU) is leading the way in medical innovation with a focus on developing advanced therapies for kidney and organ care. The company will be presenting alongside world-class headliners such as Zack Kass, former Head of Go-To-Market at OpenAI where ChatGPT was created, and “Shark Tank” stars Kevin O’Leary, Robert Herjavec, and Daymond John.
The Law Offices of Frank R. Cruz reminds investors of the upcoming September 6, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired SeaStar Medical Holding Corporation (“SeaStar” or the “Company”) (NASDAQICU) securities between October 31, 2022 and March 26, 2024, inclusive (the “Class Period”).
Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of all purchasers of securities of SeaStar Medical Holding Corporation (NASDAQ: ICU, ICUCW) between October 31, 2022 and March 26, 2024. SeaStar describes itself as a “medical technology company developing extracorporeal therapies to reduce the consequences of excessive inflammation on vital organs.”
LOS ANGELES, Sept. 03, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against SeaStar Medical Holding Corporation (“SeaStar” or “the Company”) (NASDAQICU) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
NEW YORK, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of CVS Health Corporation (NYSECVS), Walgreens Boots Alliance, Inc. NASDAQ: WBANASDAQWBA)(NASDAQ: ICUNASDAQICU, and Bolt Biotherapeutics (NASDAQ: BOLTNASDAQ). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In SeaStar To Contact Him Directly To Discuss Their Options
NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of CVS Health Corporation (NYSECVS), Walgreens Boots Alliance, Inc. NASDAQ: WBANASDAQWBA)(NASDAQ: ICUNASDAQICU, and Bolt Biotherapeutics (NASDAQ: BOLTNASDAQ). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In SeaStar To Contact Him Directly To Discuss Their Options
NEW YORK, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of CVS Health Corporation (NYSECVS), FutureFuel Corp. NYSE: FFNYSEFF)(NASDAQ: ICUNASDAQICU, and Bolt Biotherapeutics (NASDAQ: BOLTNASDAQ). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
LOS ANGELES, Aug. 20, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against SeaStar Medical Holding Corporation (“SeaStar” or “the Company”) (NASDAQICU) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
NEW YORK, Aug. 16, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of NIKE, Inc. (NYSENKE), FutureFuel Corp. NYSE: FFNYSEFF)(NASDAQ: ICUNASDAQICU, and Bolt Biotherapeutics (NASDAQ: BOLTNASDAQ). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
LOS ANGELES, Aug. 13, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against SeaStar Medical Holding Corporation (“SeaStar” or “the Company”) (NASDAQICU) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
NEW YORK, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of NIKE, Inc. (NYSENKE), FutureFuel Corp. NYSE: FFNYSEFF)(NASDAQ: ICUNASDAQICU, and Bolt Biotherapeutics (NASDAQ: BOLTNASDAQ). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In SeaStar To Contact Him Directly To Discuss Their Options
NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of CVS Health Corporation (NYSECVS), Walgreens Boots Alliance, Inc. NASDAQ: WBANASDAQWBA)(NASDAQ: ICUNASDAQICU, and Bolt Biotherapeutics (NASDAQ: BOLTNASDAQ). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
LOS ANGELES, Aug. 06, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against SeaStar Medical Holding Corporation (“SeaStar” or “the Company”) (NASDAQICU) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
NEW YORK, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of NIKE, Inc. (NYSENKE), FutureFuel Corp. NYSE: FFNYSEFF)(NYSE: RBLXNYSERBLX, and SeaStar Medical Holding Corporation (NASDAQ: ICUNASDAQ). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In SeaStar To Contact Him Directly To Discuss Their Options
